Incyte Corp.’s Zynyz (retifanlimab-dlwr) has received another U.S. FDA approval and put some distance between it and a 2021 ...

Rebrain SAS's Optimmri platform received European Medical Device Regulation CE mark certification to enable surgeons to ...

Microsatellite instability (MSI), which results from defects in the DNA mismatch repair system, is an important biomarker in colorectal cancer. While the MSI-high (MSI-H) status predicts response to ...

Even before the Trump administration’s executive order wiping out the concept of diversity, equity and inclusion, the statistics on female representation in the biotech industry painted a story of ...

In what represents just the company’s third PCT filing, Houston-based Starling Medical Inc.’s co-founders, Hannah McKenney ...

The BioWorld Drug Developers Index underperformed both the Nasdaq Biotechnology Index (NBI) and the Dow Jones Industrial ...

Rhabdomyosarcoma is an aggressive soft tissue cancer that primarily affects children, accounting for around 7% of all ...

It’s been a big week for Inozyme Pharma Inc. On the heels of a promising interim readout for phase III-stage enzyme replacement therapy (ERT) candidate INZ-701 in ENPP1 deficiency, the firm agreed to ...

Zip Diagnostics Pty Ltd., Menzies School of Health Research and Axxin Pty Ltd., a Melbourne, Australia-based diagnostic ...

Therini Bio raised an additional $39 million in its series A financing round, bringing the total for the round to $75 million. The capital will be used to advance its fibrin-targeting immunotherapies ...

Gene and cell therapies (GCTs) can target the kidney to treat congenital, acute or chronic diseases affecting this organ.

Quralis Corp. has entered into a number of agreements with the aim of advancing the treatment of fragile X syndrome, a genetic condition caused by a mutation of a single gene – fragile X messenger ...